Skip to main content

TableĀ 1 Patient characteristics and CETC examination results

From: Influence of endocrine therapy on the ratio of androgen receptor (AR) to estrogen receptor (ER) positive circulating epithelial tumor cells (CETCs) in breast cancer

Clinico-pathological characteristics

Number of patients (%) with CETCs

Median of CETC counts

P-value

Median (%) of AR positive CETCs

P-value

Median (%) of ER positive CETCs

P-value

Age (years)

ā€‰Ā ā‰¤ā€‰50

26 (39)

85

0.001

90

0.98

50

0.91

ā€‰Ā >ā€‰50

40 (61)

30

89

50

Tumor size

Ā T1

29 (44)

35

0.34

83

0.42

50

0.86

Ā T2

34 (51)

35

80

50

Ā T3

2 (3)

120

73

62

Ā n.a

1 (2)

Ā Ā Ā 

Lymph node metastasis

Ā Positive

25 (38)

40

0.63

86

0.04

50

0.63

Ā Negative

40 (61)

35

93

50

Ā n.a

1 (1)

Ā Ā Ā 

Distant metastasis

Ā Positive

7 (11)

85

0.11

88

0.99

49

0.97

Ā Negative

58 (88)

35

89

50

Ā n.a

1 (1)

Ā Ā Ā 

Stage

Ā I/II

49 (74)

30

0.009

90

0.93

51

0.16

Ā III/IV

17 (26)

95

89

62

HER2 status

Ā Positive

21 (32)

35

0.58

89

0.93

56

0.37

Ā Negative

45 (68)

35

90

52

ER/PR status

Ā Positive

51 (77)

35

0.97

87

0.74

52

0.82

Ā Negative

15 (23)

35

88

46

Radiation

Ā Yes

24 (36)

40

0.93

92

0.19

48

0.27

Ā No

34 (52)

40

88

52

Ā n.a

8 (12)

Ā Ā Ā 

Hormone receptor status

Ā TNBC

10 (16)

55

0.31

91

0.02

56

0.55

Ā ER/PR pos.

51 (84)

35

83

46

Hormone therapy

Ā Yes

33 (50)

35

0.77

89

0.57

47

0.07

Ā No

32 (49)

35

91

60

Ā n.a

1 (1)

Ā Ā Ā 

Chemotherapy

Yes

30 (45)

50

0.51

90

0.47

52

0.96

No

36 (55)

35

88

48

Tamoxifen therapy

Ā Yes

22 (33)

35

0.64

90

0.75

45

0.042

Ā No

43 (66)

35

91

58

Ā n.a

1 (1)

Ā Ā Ā 

Aromatase inhibitor

Ā Yes

19 (29)

50

0.29

85

0.22

50

0.35

Ā No

46 (70)

35

91

39

Ā n.a

1 (1)

Ā Ā Ā 
  1. Statistically significant values are in italics